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Objective: Cytomegalovirus (CMV), a ubiquitous virus belonging to the herpes family, is known 
to be transmitted frequently to developing fetuses in pregnancy. In an   immunocompromised state 
like pregnancy, primary infection through blood transfusion or reactivation of a latent CMV 
infection can cause severe illness. The study was carried out to determine the seroprevalence 
of the immunoglobulin G (IgG) antibody to cytomegalovirus amongst pregnant women in 
  correlation with previous exposure to blood transfusion.
Methods: A cross sectional study was carried out amongst 179 HIV negative pregnant women 
attending the antenatal clinic of Lagos State University Teaching Hospital (LASUTH), Ikeja, 
Nigeria. Five mL of blood was collected and stored in a plain bottle, centrifuged on the same day 
and the serum stored at −20°C. All samples were screened for anti-CMV IgG antibodies using 
the enzyme linked immunosorbent assay (ELISA). Consenting participants were instructed to fill 
a semi-structured questionnaire to obtain demographic and other related information. Statistical 
analysis of the results was done using Pearson’s chi squared test for analytical assessment.
Results: A total of 97.2% of the pregnant women recruited for this study were anti-CMV 
IgG positive. Out of the 179 recruited for the study 174 responded to the question on previous 
history of blood transfusion, 14.9% of the respondents (26 of 174) had a previous history of 
blood transfusion and all tested positive to the anti-CMVIgG antibody. However, past history 
of blood transfusion and educational level were found to be insignificant to the risk of acquiring 
CMV infection.
Conclusion: The seroprevalence of the CMV antibody amongst pregnant women in this 
environment is high in relation to findings in other developing countries. There is the need to 
assess anti-CMV immunoglobulin M antibodies in pregnant women, which is a determinant 
of active infection.
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Introduction
Cytomegalovirus belongs to the subfamily of herpes known as β herpes and it is 
found universally in various geographic locations. CMV infection is also known to 
be frequently transmitted to a developing fetus. This virus remains the leading cause 
of congenital viral infection and a significant cause of transfusion-acquired infections 
in patient populations.1 Its clinical manifestations include asymptomatic forms, severe 
fetal damage, and death in rare cases due to spontaneous abortion.
For most healthy people who acquire CMV infection after birth or through 
blood transfusion, there are few symptoms and no long term sequelae. Therefore, 
for the vast majority of individuals, CMV infection is innocuous.2 However, CMV International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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infection is important in pregnant women because of their 
immunocompromised state and risk of infection to the fetus 
whose immune   system is not fully developed. Furthermore, 
10% to 15% of the children who are asymptomatic at birth 
may develop late sequelae, especially hearing defects, after 
a period of months or years.3
Once a person becomes infected, the virus remains 
alive but usually dormant within the individual’s body for 
life. Recurrent disease rarely occurs unless the immune 
system is compromised. It was reported that the risk of 
fetal   damage is greater if the primary infection occurs 
  during the first   trimester of pregnancy.4–6 The prevalence of 
congenital   infection ranges from 0.2% to 2.5% in different 
populations,7–13 with groups at greater risk including Black or 
Asian women, those from a low socioeconomic background, 
and those that are born prematurely.10
The prevalence of congenital infection varies with 
the prevalence of the infection in the population.14 The 
seroprevalence of CMV among women of childbearing age 
ranges from 35% to 95% in different countries.5,14–17 It is 
more widespread in developing countries and in areas of 
lower socioeconomic conditions.18
The rate of seropositivity of anti-CMV   immunoglobulin 
G(IgG) enzyme linked immunosorbent assay (ELISA) 
antibodies of pregnant women in Turkey was reported to be 
98.5%19 and 84% in Spain.20 These rates are much higher 
than the typical European rate but similar to the rate obtained 
amongst Black pregnant women.
An overall rate of 87% of anti-CMV IgG ELISA   antibodies 
in pregnant women was reported in Singapore,21 100% in 
Thailand,21 and 93% in Iranian women of   childbearing age.22
Since CMV is transmitted through blood transfusion, 
the strict use of blood during pregnancy and labor cannot 
be overemphasized as some of the pregnant women could 
be CMV negative.
Several studies and data support the transmission of CMV 
from seropositive blood donors to susceptible recipients in a 
variety of settings.23,24 Topin et al25 provided the first biochemical 
evidence for transfusion associated CMV infection. The study 
reported that monocyte latently infected with CMV represent 
the primary vector for Transfusion Associated-CMV (TA-CMV) 
which can be largely abrogated by transfusing at risk patients 
with either seronegative units or blood filtered to remove white 
blood cells. Lamberson et al26 also determined that a decreased 
incidence of transfusion associated with CMV (TA-CMV) infec-
tion occurred when only blood products that tested negative for 
CMV immunoglobulin M (IgM) were used.
Two hypotheses have been investigated as possible 
mechanisms for CMV transmission by blood. First, since 
CMV resides in a latent state in the infected host, it has 
been proposed that all CMV-seropositive blood donors can 
transmit the latent virus,27,28 following transfusion. In this 
case latent virus is reactivated and may cause active CMV 
infection in the recipient. Latency following a primary 
infection may be punctuated by periodic reactivation that 
gives rise to recurrent infections, and in utero transmission 
may occur during either primary or recurrent infections.29 
Yeager and colleagues published an excellent study of 
TA-CMV infections in newborns to prove this fact.30 CMV-
specific antibody of the IgM class has been recognized as a 
marker of active or recent primary infection with the virus. 
Recent reports have shown a positive correlation between 
post transfusion CMV infection and the receipt of blood from 
CMV IgM-positive donors.31
Such units of blood may be used for CMV negative 
pregnant women thus increasing the incidence of CMV 
in the population with its consequent embryopathy such 
as sensorineural hearing loss, chorioretinitis, mental 
retardation and fetal death. CMV embryopathy should 
be a major concern for public health irrespective of the 
percentage of babies affected. Therefore, the need to 
determine the seroprevalence of the CMV antibody in 
pregnant women cannot be overemphasized. This will 
underscore the significance of CMV screening in blood 
units for use in pregnancy and labor. This is necessary to 
avoid the transmission of CMV infected blood to women 
who are CMV seronegative.
Subjects and method
study population
A cross sectional study was carried out using the antenatal 
clinic of Lagos State University Teaching Hospital 
(LASUTH), Ikeja, Nigeria. The clinic registers about 
150 patients daily and all consenting newly registered 
pregnant women were recruited for the study between July 1 
and August 15, 2008. However, approval was obtained from 
the institution’s research and ethics committee (LASUTH 
Health Research and Ethics Committee). Participants were 
instructed to fill out a structured questionnaire including 
demographic information and previous exposure to blood 
transfusion. Immunocompromised participants with a 
history of chronic illness, such as hepatitis, sickle cell 
disease, renal disorders, gestational diabetes and HIV 
infection were excluded.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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collection of samples
A blood sample of 5 mL was collected into a sterile, nonan-
ticoagulated bottle from each consenting participant. The 
sample was centrifuged and the serum separated into a sterile 
bottle and stored at −20°C.
cytomegalovirus serology
Sera were tested for IgG CMV using the ELISA test. The 
CMV-specific IgG antibodies were studied by the   commercial 
Dia.Pro Diagnostic Bioprobe CMV IgG (Milan, Italy) 
  according to the manufacturer’s instructions. All specimens 
were analyzed using the enzyme immunoassay test. The 
  cutoff of IgG was set at 0.5 World Health Organization 
(WHO) IU/m (calibrator 2) by the kit’s manufacturer.
Samples with a concentration $0.5 WHO IU/mL were 
considered positive for CMV IgG, while samples with a 
concentration below the cut off were considered as negative 
results. The controls and the calibrators passed the validation 
check recommended by the manufacturer of the kit.
statistical analysis
Statistical analysis of results was done using the statistical 
package for social science (SPSS 16.0, IBM, USA). The 
Pearson chi squared test and multiple comparisons   involving 
post-hoc analysis such as the Bonferonni correction 
were used for the analytic assessment and the differences 
were considered to be statistically significant when the 
P-value obtained was ,0.05.
Results
A total of 179 pregnant women were enrolled into the study. 
About 50.8% of them were between the ages of 25–30 years 
and 0.60% were under 18 years (Table 1). Almost all of them 
(97.20%) had anti-CMV IgG antibodies. The majority of 
those (89 of 179) who had anti-CMVIgG antibodies were 
between parity 1 and 4 (Table 2). It was observed that most 
(70.40%) of the patients had tertiary education, followed 
by 24.60% with secondary education. Less than 2% had no 
formal education (Table 3). However, levels of education 
did not correlate with CMV status (P = 0.14).
The majority (86.03%) of the subjects were married and 
most of them had anti-CMV IgG antibodies, 11.17% were 
single and 2.7% were separated. (P = 0.11) (Table 4).
One hundred and seventy four of the participants 
responded to the question on past history of transfusion while 
14.94% of the 174 respondents (26 of 174) had a previous 
history of blood transfusion and all tested positive to the 
anti-CMV IgG antibody. Equally, 148 of the 174 (85.05%) 
subjects had no past history of blood transfusion and 143 of 
the 148 (96.62%) tested positive to anti-CMV IgG antibodies, 
but only 5 of 148 (3.37%) tested negative to the IgG CMV 
P = 0.77 (Table 5). Hence an association cannot be established 
between transfusion history and anti-CMV IgG positivity.
Multiple comparisons involving post hoc analysis such as 
the Bonferonni correction were done on level of   education/
CMV serostatus, marital status/CMV serostatus, parity/CMV 
serostatus, and age/CMV serostatus. The tests of homogeneity 
of variances were 0.73, 0.11, 0.78, and 0.74 respectively which 
were not significant, hence the use of Bonferonni rather than 
the Tamhane’s T2 post-hoc test. None of the mean differences 
between the groups compared by the test was significant at 
0.05 levels. Post-hoc analysis could not be performed on previ-
ous history of blood transfusion and anti-CMV seropositivity 
because there were fewer than three groups.
Discussion
The 97.20% seropositivity rate of IgG anti-CMV antibodies 
observed in this study amongst pregnant women is in keep-
Table 1 Age in years with cMV serostatus
Age in years anti-CMV IgG +ve anti-CMV IgG -ve
,18 2 0
19–24 18 1
25–30 89 2
31–35 45 1
36–40 17 0
41 and above 3 1
Note: P = 0.14.
Abbreviations: cMV, cytomegalovirus; Igg, immunoglobulin g.
Table 2 Parity with cMV seropositivity
Parity anti-CMV IgG +ve anti-CMV IgG -ve
0 60 3
1–4 89 2
5 and above 25 0
Note: P = 0.42.
Abbreviations: cMV, cytomegalovirus; Igg, immunoglobulin g.
Table 3 education with cMV seropositivity
Education anti-CMV IgG +ve anti-CMV IgG -ve
none 3 0
Primary 5 1
secondary 42 2
Tertiary 124 2
Note: P = 0.14.
Abbreviations: cMV, cytomegalovirus; Igg, immunoglobulin g.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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ing with several studies. As early as 1973, Krech reported 
that CMV antibodies are more prevalent in developing 
countries and areas of lower socioeconomic conditions in 
comparison to developed countries.18 Tookey et al,32 in a 
prospective study amongst pregnant women in London, found 
a seroprevalence as high as 88.2% in the first pregnancy 
of women. Their study was, however, ethnically diverse, 
with the highest prevalence recorded in Asian women at 
88.2%, 77.2% in Black women, and the lowest in White   
women at 45.9%.
The lowest percentage of 45.9% derived amongst the 
White pregnant women population reported by Tookey 
et al, is similar to the overall rate of anti-CMV IgG ELISA 
of 55.1% reported amongst French women,33 with 68.3%,34 
30.4%,35 39%–94%36 and 56.8%37 in Italy, Ireland, the USA, 
and Australia respectively.
It is noteworthy in this study that age, parity, marital status, 
and educational level were not associated with the risk of CMV 
positivity, because they did not reach significant levels.
Blood transfusion-associated CMV infection has been 
proven extensively.9–24 Akinbami (2009) et al38 reported a 96% 
IgG anti-CMV and 19.5% IgM anti-CMV antibodies sero-
prevalence amongst healthy blood donors in Lagos, Nigeria. 
This is quite significant because one out of every four units 
of blood donated is acutely infected by CMV because IgM 
anti-CMV antibody is a marker of active or recent primary 
infection with the virus. A pregnancy-related hemorrhage 
is still a major cause of peripartal morbidity and mortality 
in developing countries and blood transfusion rates may be 
high in these countries. In a Nigerian audit of 463 consecu-
tive cesarean sections and blood transfusions within a period 
of 3 years,39 25.2% cesarean section cases were transfused. 
A total of 67.2% of caesarean sections of these cases were 
emergency.39 The rate of blood transfusion for the various 
indications were as follows: malpresentation (excluding 
breech) 66.7%; placenta previa 59.1%; uterine rupture 55.6%; 
breech delivery 32%; obstructed labor 28.2%; previous baby 
25%; previous cesarean section 17.0%; severe preeclampsia 
11.1%; fetal distress 10.7%; and   others, 10.3%. Akinola 
et al40 also reported in a similar study a   transfusion rate of 
13.6% amongst cesarean section patients in   southwestern 
Nigeria.
Despite the reported rate of lower seroprevalence 
of anti-CMV IgG ELISA antibodies amongst higher 
  socioeconomic classes and in developed nations,18 lower 
rates of blood transfusion of 4.9% and 5.4% were reported by 
Dathie et al41 and Rouse et al42 respectively. In Canada43 the 
overall rate of blood transfusion for postpartum hemorrhage 
was 0.31%, and 0.49%, 0.28%, 0.23% for emergency 
caesarean section, vaginal delivery, and elective cesarean 
section respectively.
In developing countries, the higher rate of anti-CMV 
IgG seroprevalence associated with higher requirements 
for blood in pregnant women poses a grave risk of CMV 
embryopathy. There is the need to assess anti-CMV IgM 
antibodies in pregnant women in these countries which is a 
marker of acute infection and more directly related to CMV 
embryopathy.
Previous history of blood transfusion and socioeconomic 
status were, however, found in this study not to be significant 
factors to CMV antibody positivity. This might be related 
to the high seroprevalence of anti-CMV IgG in the Nigerian 
population. Future studies in populations with similarly high 
seroprevalence may need higher recruitment numbers.
Conclusion
The seroprevalence of anti-CMV IgG is very high among 
pregnant women in Nigeria. Based on previous studies that 
showed a decrease in the incidence of CMV disease when 
blood was screened for CMV (IgM), the incidence of the 
disease can be decreased in Lagos if blood is screened for 
CMV . Previous blood transfusion exposure was insignificant 
in the risk of transmission.
Limitations of this study
1.  Reliability of information on blood transfusion pro-
vided by patients and the possible reasons for finding 
small numbers of those who have been previously 
transfused.
Table 4 Marital status with cMV seropositivity
Marital status anti-CMV IgG +ve anti-CMV IgG -ve
single 18 2
Married 151 3
separated 5 0
Note: P = 0.11.
Abbreviations: cMV, cytomegalovirus; Igg, immunoglobulin g.
Table 5 relationship between blood transfusion and anti-cMV 
Igg seropositivity
Past transfusion  
history
anti-CMV IgG +ve anti-CMV IgG -ve
Yes 26 0
no 143 5
Note: P = 0.77.
Abbreviations: cMV, cytomegalovirus; Igg, immunoglobulin g.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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2.  The use of IgG ELISA assay rather than IgG and IgM 
in determining seroprevalence of CMV in pregnant 
women.
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